502 MI130004, an antibody–drug conjugate including a novel payload of marine origin: Evidences of in vivo activity
Aviles, P.M, Guillen, M.J, Dominguez, J.M, Muñoz-Alonso, M.J, Garcia-Fernandez, L.F, Garranzo, M, Martinez, V, Francesch, A, Munt, S, Galmarini, C.M, Cuevas, C
Published in European journal of cancer (1990) (01.11.2014)
Published in European journal of cancer (1990) (01.11.2014)
Get full text
Journal Article
244 Development of xenoimplants from germline BRCA1/2 mutant breast cancer (BC) for the identification of predictive biomarkers, mechanisms of resistance against poly(ADP-ribose) polymerase (PARP) inhibitors and evaluation of novel therapies
Cruz, C, Ibrahim, Y, Morancho, B, Anton, P, Grueso, J, Cozar, P, GuzmÁn, M, Avilés, P.M, Guillen, M.J, Galmarini, C, Arribas, J, Baselga, J, Balmaña, J, Serra, V
Published in European journal of cancer (1990) (01.11.2014)
Published in European journal of cancer (1990) (01.11.2014)
Get full text
Journal Article
Lurbinectedin (PM01183) exhibits antitumor activity in PARP-inhibitor resistant germline BRCA PDX and lacks cross-resistance with cisplatin
Cruz, C., Caratu, G., Llop-Guevara, A., Castroviejo, M., Gutierrez-Enriquez, S., Morancho, B., Campa, E. Álvarezdela, Prudkin, L., Nuciforo, P., Arribas, J., Vivancos, A., Cruz, Xdela, Galmarini, C., Avilés, P.M., Saura, C., Díez, O., Serra, V., Balmaña, J.
Published in Annals of oncology (01.10.2016)
Published in Annals of oncology (01.10.2016)
Get full text
Journal Article